Oncology Research Center, Federal University of Pará, Belem 66075-110, Brazil.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5T 2S8, Canada.
Int J Mol Sci. 2023 Dec 18;24(24):17582. doi: 10.3390/ijms242417582.
Papillary subtypes of renal-cell carcinoma (pRCC) represent 10-15% of the cases and commonly have MET alterations. This systematic review and single-arm meta-analysis evaluated MET inhibitor therapy (METi) efficacy and safety in adults with confirmed advanced pRCC. The search strategy included PubMed, Web-of-science, Cochrane, and Scopus. We used the DerSimonian/Laird random effect model for all analyses; -value < 5% was considered significant, and heterogeneity was assessed with I. Three clinical trials and six cohort studies were included with 504 patients; 31% were MET-driven. Our pooled analysis demonstrated an objective response rate (ORR) in MET-driven, MET-independent, and overall patients of: 36% (95%CI: 10-62), 0% (95%CI: 0-3), and 21% (95%CI: 1-41), respectively. One-year disease control and progression-free survival rates were, respectively, 70% (95%CI: 52-88) and 15% (95%CI: 10-20). Twelve- and twenty-four-month survival rates were, respectively, 43% (95%CI: 23-64) and 10% (95%CI: 0-30). The prevalence of adverse events of any grade and grades 3-5 were 96% (95%CI: 91-100) and 44% (95%CI: 37-50), respectively. We suggest METi has anti-tumor activity and is tolerable in patients with advanced pRCC.
乳头状肾细胞癌 (pRCC) 的亚型占病例的 10-15%,通常存在 MET 改变。本系统评价和单臂荟萃分析评估了 MET 抑制剂治疗 (METi) 在确诊为晚期 pRCC 的成人中的疗效和安全性。检索策略包括 PubMed、Web-of-science、Cochrane 和 Scopus。我们对所有分析均采用 DerSimonian/Laird 随机效应模型;P 值<0.05 被认为具有统计学意义,使用 I 来评估异质性。纳入了三项临床试验和六项队列研究,共 504 名患者;31%为 MET 驱动。我们的汇总分析显示,MET 驱动、MET 非驱动和总体患者的客观缓解率 (ORR) 分别为:36%(95%CI:10-62)、0%(95%CI:0-3)和 21%(95%CI:1-41)。一年疾病控制率和无进展生存率分别为 70%(95%CI:52-88)和 15%(95%CI:10-20)。12 个月和 24 个月的生存率分别为 43%(95%CI:23-64)和 10%(95%CI:0-30)。任何等级和 3-5 级不良事件的发生率分别为 96%(95%CI:91-100)和 44%(95%CI:37-50)。我们建议 METi 对晚期 pRCC 患者具有抗肿瘤活性且耐受良好。